Organon & Co. (OGN) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-24

How it makes money

Organon earns revenue by selling women's health products and general medicines through various global channels including drug wholesalers and retailers.

Organon generates its revenue across two principal product categories: Women's Health and General Medicines. The Women's Health portfolio comprises prescription products focused primarily on contraception, such as Nexplanon and NuvaRing, and fertility treatments like Follistim AQ. The General Medicines portfolio includes biosimilars spanning immunology and oncology, alongside established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management.

These products are distributed globally across more than 140 countries and territories. Customers and distribution partners include drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers.

What protects it: the moat

Management claims that proprietary product characteristics, regulatory approvals, and brand positioning protect its market position, though many established brands face generic competition.

Organon relies on a portfolio that includes long-acting reversible contraceptives, fertility treatments, biosimilars, and established brands. Many brands within the established brands portfolio lost exclusivity years ago and have faced generic competition for some time. Management points to intellectual property and regulatory hurdles as components of product defense, but the company also operates with limited in-house discovery and relies on external collaborations to refresh its pipeline as older products lose patent protection.

What growth costs

Organon incurs costs related to operating six manufacturing facilities, implementing restructuring initiatives, and maintaining external partnerships for product development and commercialization.

The filing does not provide a comprehensive breakdown of ongoing annual maintenance versus growth capital expenditures. However, it notes that the company operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the UK. To support its financial strategy and debt reduction goals, Organon has engaged in restructuring initiatives aimed at driving operational efficiencies and cost savings.

Additionally, because Organon has limited in-house discovery capabilities, it pursues external acquisitions, partnerships, and collaborations to expand its innovative pipeline and commercialize products originated by biopharmaceutical innovators.

What could damage it

The loss of market exclusivity for key products without sufficient replacement revenue could permanently impair Organon's earnings and cash flows.

Organon depends heavily on a select group of leading products to generate its profits and cash flows. If competitors successfully introduce generic alternatives or if key products fail to retain market exclusivity—such as the upcoming expiration of rod patents for Nexplanon in 2027—revenue could decline significantly. Because the company maintains limited in-house early research capabilities and relies on external partnerships for pipeline expansion, an inability to successfully replace lost sales from older products would constrain future profitability and hinder debt reduction efforts.

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Other companies in Drug Manufacturers - General